ALY688ER
Duchenne Muscular Dystrophy (DMD)
Phase 1Active
Key Facts
About Allysta Pharmaceuticals
Allysta Pharmaceuticals is a clinical-stage biotech developing first-in-class peptide therapeutics that activate adiponectin receptor signaling, a pathway with anti-fibrotic, anti-inflammatory, and cell-regenerative effects. Its lead asset, ALY688ER, is in human testing for Duchenne muscular dystrophy and has shown promise in preclinical models for a range of fibrotic and inflammatory conditions. The company is led by an experienced team with deep expertise in drug development and is backed by venture capital, positioning it to advance its novel platform in areas of significant unmet need.
View full company profileTherapeutic Areas
Other Duchenne Muscular Dystrophy (DMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| DT-DEC01 | Dystrogen Therapeutics | Phase 1 |
| Skeletal Muscle Regeneration Program | IPS HEART | Pre-clinical |
| KYMBEE (deflazacort) | Upsher-Smith | Approved |
| AVGN7 + AVGND | AAVogen | Pre-clinical |
| Myomatrix Stabilization Program | Strykagen | Preclinical |
| RIPPLE™ (implied) | SonoThera | Preclinical |
| Vamorolone (AGAMREE) | ReveraGen BioPharma | Approved |
| AGAMREE (vamorolone) | Catalyst Pharmaceuticals | Marketed |
| EDG-5506 | Edgewise Therapeutics | Phase 2 |
| ELEVIDYS (delandistrogene moxeparvovec-rokl) | Sarepta Therapeutics | Marketed / Phase 3 |
| SRP-5051 (vesleteplirsen) | Sarepta Therapeutics | Phase 2 |
| EXONDYS 51 (eteplirsen) | Sarepta Therapeutics | Marketed |